Pharmaceutical company IBSA Derma, the UK and Ireland subsidiary of global pharmaceutical leader IBSA, has announced that it will assume responsibility for the distribution of injectables Profhilo, Aliaxin and Viscoderm.
The transition marks the conclusion of a decade-long partnership with training provider HA-Derma, which managed the distribution of Profhilo, Aliaxin and Viscoderm for the past 10 years. HA-Derma confirms that all services will continue until December 31, 2025.
From January 1, 2026, IBSA Derma UK&I will oversee the production of ultrapure hyaluronic acid using its patented NAHYCO technology, while also maintaining and expanding hologram-based product verification and managing logistics and distribution across the UK and Ireland.
The company also shared its commitment to strengthening local business support, enhancing medical education and ensuring rapid product replenishment for its partners.
Alex Stuart, head of IBSA Derma UK&I, commented, “Taking the reins in the UK & Ireland marks a pivotal milestone for IBSA Derma. The successful growth of Profhilo under HA-Derma has set apart injectable bioremodelling. With Profhilo Structura, Aliaxin and Viscoderm poised to reach new audiences, we’re excited to launch IBSA Derma UK&I and deepen our partnership with practitioners. This transition enables us to deliver seamless support, drive innovation in aesthetics and ensure every patient benefits from the highest standards of safety and effectiveness.”
Iveta Vinklerova, director of HA-Derma, also commented, “We’re proud of the legacy we’ve built. From launching Profhilo to pioneering hologram verification, our focus has always been on empowering practitioners with trust, education and results. Our shared priority is to support practitioners every step of the way, so they experience a seamless handover and continued confidence in the brands they know and trust.”